Basel | | Investor Type | Corporate VC |
| Type of Fund | Corporate VC |
| Industries | BioTech • HealthTech (& Fitness) • Material Science • Pharmaceutical (& Medicine) |
| Stages | Seed, Series A, Series B |
| Investing | United States • United Kingdom • Canada • Germany • France • Spain • China • Switzerland • Netherlands • Singapore • Israel • Austria • Finland • New Zealand • Iceland • Korea • Ireland |
| Investment Range | $5,000,000 - $10,000,000 |
| Investment Sweet Spot | $7,500,000 |
| Assets Under Management | $750,000,000 |
What is Novartis Venture Fund?
Novartis Venture Fund (NVF) is a corporate venture capital (VC) firm dedicated to fostering innovation in the life science industry. With a commitment to aiding significant patient benefit, NVF aims to generate superior returns by investing in and nurturing promising innovative life science companies. The fund operates with committed capital surpassing USD 750 million and maintains a diverse portfolio with more than 40 companies situated in North America and Europe.
They are active participants in their investment companies' growth, with a focus on novel therapeutics and platforms that present potential solutions for unmet patient needs in healthcare globally. Investment criteria for NVF range from an investment minimum of USD 5,000,000 to a maximum of USD 10,000,000, aiming at a 'sweet spot' of approximately USD 7,500,000 for each investment.
As a strategic investor, NVF targets various stages of company development, including Seed, Series A, and Series B funding rounds. This focus allows them to be hands-on in their approach to investment, actively contributing to board and management efforts.
The team, split between Basel, Switzerland, and Cambridge, Massachusetts, comprises experienced professionals with a strong track record in life science and business growth, particularly in innovative drug development encompassing broad therapeutic areas and drug modalities. The NVF team leverages their expertise and experience to create real clinical impact alongside financial success.
They are guided by the principle of investing in the future health of patients worldwide and are constantly seeking transformative opportunities in Biotech, HealthTech, Material Science, and the Pharmaceutical industry.
What they say:
We are a venture capital firm focused on specific scientific advancements.
What we look for: We invest in companies developing novel therapeutics and platforms.
Novartis Venture Fund's investments on record
What are the investment firms similar to Novartis Venture Fund
TX Ventures
Seier Capital
Nirmata-ai
AEVIS VICTORIA SA
Arcanys Ventures
b2venture
BaseLaunch
Exelixis Capital
Voltimum
Oxford Technology Management Ltd.
Contact over 100,000 investors!
Built by serial entrepreneurs and ex-VCs, Angels Partners helps entrepreneurs connect with relevant investors in their industry.
With over 100K+ listed investors, our mission is to help founders secure meetings & accelerate their fundraising.
View previous deals, filter by deal size, industry, location and more. It's the fastest way to build a target investor list.
We also built a community of hundreds of investors actively prospecting & investing directly on Angels Partners.
Register to become visible to a large community of investors on our platform.
- Prime Founders
- 71-75 Shelton Street, Covent Garden, WC2H 9JQ
- London, U.K.
- contact@angelspartners.com
